Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$176.37 USD
-1.88 (-1.05%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $176.31 -0.06 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Becton, Dickinson and Company has a market cap of $51.09B, which represents its share price of $178.25 multiplied by its outstanding shares number of 286.61M. As a large-cap company, BDX's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BDX 176.37 -1.88(-1.05%)
Will BDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDX
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BD Partners With Waters to Build High-Volume Diagnostics Leader
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
Top Stock Reports for Amazon.com, Home Depot & Cisco Systems
Other News for BDX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
BDX Unveils At-Home HPV Test to Revolutionize Cervical Cancer Screening | BDX stock news
BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening ...
BDX Gains FDA Approval for BD Veritor System to Detect COVID-19 Antigens
BD gets FDA nod for rapid COVID-19 test